Dexamethasone as a chemoprotectant in cancer chemotherapy: Hematoprotective effects and altered pharmacokinetics and tissue distribution of carboplatin and gemcitabine

Cancer Chemotherapy and Pharmacology

Volumn 53, Issue 6, 2004, Pages 459-467

  Wang, Hui ^a   Li, Mao ^a   Rinehart, John J ^b   Zhang, Ruiwen ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Carboplatin; Chemoprotection; Dexamethasone; Gemcitabine

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DEXAMETHASONE; GEMCITABINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD CELL COUNT; BLOOD TOXICITY; BONE MARROW; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CYTOPENIA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG MECHANISM; DRUG TISSUE LEVEL; DRUG UPTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOACTIVITY; SPLEEN; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AREA UNDER CURVE; BONE MARROW; CARBOPLATIN; DEOXYCYTIDINE; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ANTAGONISM; GLUCOCORTICOIDS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LONGEVITY; MALE; MICE; MICE, INBRED STRAINS;

EID: 2542491442     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0759-9     Document Type: Article

References (32)

1. Kaufman D, Chabner BA (1996) Clinical strategies for cancer treatment: the role of drugs. In: Chabner BA, Longo DL (eds) Cancer chemotherapy and biotherapy. Lippincott-Raven, Philadelphia, pp 1-16
2. Demetri GD, Anderson KC (1995) Bone marrow failure. In: Clinical oncology. Churchill Livingstone, NY, p 443
3. Mackal CL (2000) T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review. Stem Cells 18:10
4. Ganser A, Karthaus M (1996) Clinical use of hematopoietic growth factors. Curr Opin Oncol 8:265
5. Griffin JD (1997) Hematopoietic growth factors. In: DeVita VT, Hellman S, Rosenberg SA (eds)Cancer: Principles and practice of oncology, 5th edn. Lippincott, Philadelphia, p 2639
6. Joyce R, Chervenick P (1977) Corticosteroid effect on granulopoiesis in mice after cyclophosphamide. J Clin Invest 60:277
7. Kriegler A, Bernardo D, Verschoor S (1994) Protection of murine bone marrow by dexamethasone during cytotoxic chemotherapy. Blood 83:65
8. Rinehart J, Delamater E, Keville L (1994) Corticosteroid modulation of interleukin-1 hematopoietic effects and toxicity in a murine system. Blood 84:1457
9. Rinehart J, Keville L, Measel J (1995) Corticosteroid alteration of carboplatin-induced hematopoietic toxicity in a murine model. Blood 86:4493
10. Rinehart JJ, Keville L (1997) Corticosteroid alteration of carboplatin induced hematopoietic toxicity: comparison of efficacy in normal and hematopoietically impaired tumor bearing mice. Cancer Radiopharm 2:101
11. Aman MJ, Keller U, Derigs G (1994) Regulation of cytokine expression by interferon-α in human bone marrow stromal cells: inhibition of hematopoietic growth factors and induction of interleukin-a receptor antagonist. Blood 84:4142
12. Chudgar UH, Rundus CH, Peterson VM (1995) Recombinant human interleukin-1 receptor antagonist protects early myeloid progenitors in a murine model of cyclophosphamide-induced myelotoxicity. Blood 85:2393
13. Cashman JD, Eaves AC, Raines EW (1990) Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures. I. stimulatory role of a variety of mesenchymal cell activators and inhibitory role of TGF-β. Blood 75:96
14. Futami H, Jansen R, MacPhee M (1990) Chemoprotective effects of recombinant human IL-1α in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy. J Immunol 145:4121
15. Dunlop D, Wright E, Lorimore S (1992) Demonstration of stem cell inhibition and myeloprotective effects of SCI-rhMIP-Iα in vivo. Blood 79:2221
16. 2 protect mice from acutely lethal doses of 5-fluorouracil and doxorubicin. J Exp Med 180:1047
17. Peters G, Van der Vijgh W (1995) Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (WR-2721): preclinical aspects. Eur J Cancer [Suppl] 31A:S1
18. Podda S, Ward M, Himelstein A, Richardson C, Flor-Weiss EDL, Smith L, Gottesman M, Pastan I, Bond A (1992) Transfer and expression of the human multiple drug resistance gene in live mice. Proc Natl Acad Sci U S A 89:9676
19. Rinehart J, Keville L, Neidhart J, Wong L, DiNunno L, Kinney P, Aberle M, Tadlock L, Cloud G (2003) Hematopoietic protection by dexamethasone or granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients treated with carboplatin and ifosfamide. Am J Clin Oncol 26:448
20. Vadhan-Raj S, Broxmeyer H, Hittelman W (1992) Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level. J Clin Oncol 10:1266
21. Broxmeyer H, Benningre L, Patel S (1994) Kinetic response of human marrow myeloid progenitor cells to in vivo treatment of patients with granulocyte colony-stimulating factor is different from the response to treatment with granulocyte-macrophage colony-stimulating factor. Exp Hematol 22:100
22. Janik J, Miller L, Smith J II (1993) Prechemotherapy granulocyte- macrophage colony stimulating factor (GM-CSF) prevents topotecan-induced neutropenia. Proc ASCO 12:1507
23. Aglietta M, Monzeglio C, Pasquino P (1993) Short-term administration of granulocyte-macrophage colony stimulating factor decreases hematopoietic toxicity of cytostatic drugs. Cancer 72:2970
24. Betticher D, Anderson H, Ranson M (1995) Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomized phase II study. Br J Cancer 72:1551
25. Duffull SB, Robinson BA (1997) Clinical pharmacokinetics and dose optimisation of carboplatin. Clin Pharmacokinet 33:161
26. Heinemann V (2002) Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials. Semin Oncol 29:9
27. Wang H, Cai Q, Zeng X, Yu D, Agrawal S, Zhang R (1999) Anti-tumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to RIα subunit of protein kinase A after oral administration. Proc Natl Acad Sci U S A 96:13989
28. Zhang R, Lu Z, Liu T, Soong SJ, Diasio RB (1993) Relationship between circadian-dependent toxicity of 5-fluorodeoxy-uridine and circadian rhythms of pyrimidine enzymes: possible relevance to fluoropyrimidine chemotherapy. Cancer Res 53:2816
29. Bullen WW, Andress LD, Chang T, Whitfield LR, Welch ML, Newman RA (1992) A high-performance liquid chromatographic assay for CI-973, a new anticancer platinum diamine complex, in human plasma and urine ultrafiltrates. Cancer Chemother Pharmacol 30:193
30. Zhang R, Diasio RB, Lu Z, Liu T, Jiang Z, Galbraith WM, Agrawal S (1995) Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochem Pharmacol 49:929
31. Matsukado K, Nakano S, Bartus RT, Black KL (1997) Steroids decrease uptake of carboplatin in rat gliomas - uptake improved by intracarotid infusion of bradykinin analog, RMP-7. J Neurooncol 34:131
32. Wang H, Li M, Rinehart JJ, Zhang R (2003) Dexamethasone increases anti-tumor activity and alters pharmacokinetics of carboplatin and gemcitabine in vivo (abstract 609). Proceedings of the 94th Annual Meeting AACR, vol. 44, p 140